Professional Seasonal Analysis for Trading

EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT)

Seasonality Analysis

Stocks 22 Years Analyzed

EyePoint Pharmaceuticals, Inc. - Common Stock Annual Seasonality Statistics

23.35%
Avg Annual Return
43.0%
Avg Monthly Win Rate
6/12
Positive Months
22
Years Analyzed

EyePoint Pharmaceuticals, Inc. - Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January 1.15%
50%
Weak
February 0.22%
32%
Weak
March -1.46%
32%
Very Weak
April BEST 17.35%
59%
Moderate
May -1.26%
38%
Very Weak
June -1.83%
33%
Very Weak
July 6.43%
67%
Strong
August -0.72%
43%
Weak
September 1.08%
43%
Weak
October -3.57%
43%
Weak
November WORST -5.71%
38%
Very Weak
December 11.67%
38%
Weak

EyePoint Pharmaceuticals, Inc. - Common Stock 2026 vs Historical Pattern

Current Position
38.37
Historical Avg Position
33.81
Deviation
+4.56
Performance
On Track

EyePoint Pharmaceuticals, Inc. - Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for EYPT with overlay patterns, custom date ranges, and more.

Create Free Account

EyePoint Pharmaceuticals, Inc. - Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

EyePoint Pharmaceuticals, Inc. - Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for EYPT across multiple timeframes.

Create Free Account

About EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT) Seasonality

EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT) has been analyzed using 22 years of historical data to identify seasonal patterns. Classified under Stocks, EyePoint Pharmaceuticals, Inc. - Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for EyePoint Pharmaceuticals, Inc. - Common Stock is historically April, with an average return of 17.35% and a win rate of 59%. Conversely, November tends to be the weakest month, averaging -5.71% return.

Looking at the full calendar year, EyePoint Pharmaceuticals, Inc. - Common Stock has an average annual return of 23.35% with an overall monthly win rate of 43.0%. Out of 12 months, 6 typically show positive average returns.

The seasonal pattern for EyePoint Pharmaceuticals, Inc. - Common Stock has a consistency score of 36.3 (Poor), based on 22 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

EyePoint Pharmaceuticals, Inc. - Common Stock Seasonality FAQ

What is the best month to buy EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT)?

Historically, April has been the best month for EyePoint Pharmaceuticals, Inc. - Common Stock, with an average return of 17.35% and a win rate of 59%. However, past performance does not guarantee future results.

What is the worst month for EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT)?

Based on historical data, November has been the weakest month for EyePoint Pharmaceuticals, Inc. - Common Stock, with an average return of -5.71%. This is a historical observation and does not guarantee future results.

How reliable is EYPT seasonality data?

The seasonality analysis for EyePoint Pharmaceuticals, Inc. - Common Stock is based on 22 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use EyePoint Pharmaceuticals, Inc. - Common Stock seasonality in my trading?

Use EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.